Abstract: This disclosure describes dynamic access control using capabilities (via dynamic access control interface (150)) on a blockchain system (180). The blockchain data structure is a time-stamped list of blocks, chained together cryptographically. In this disclosure, capabilities can be recorded on a blockchain system (via capabilities storage (170)) and thus access propagation is known. This makes revocation of access achievable by recording a new transaction, which in effect removes the previous authorization. There will be no change to transaction history and instead a new transaction records (170) the current status of the capability. An example implementation on a blockchain system (180) is given in Ethereum, which allows programs called “smart contracts” to run as transactions.

Abstract: Communications along a neural pathway are provided. The neural pathway is stimulated at a first location, in order to evoke neural responses which propagate along the neural pathway, the neural responses being modulated with data. At a second location spaced apart from the first location along the neural pathway the evoked neural responses are sensed. The sensed neural responses are then demodulated to retrieve the data. The stimulation could comprise peripheral sensory stimulation, and the second location could be at an implanted electrode array.

Abstract: This disclosure describes dynamic access control using capabilities (via dynamic access control interface (150)) on a blockchain system (180). The blockchain data structure is a time-stamped list of blocks, chained together cryptographically. In this disclosure, capabilities can be recorded on a blockchain system (via capabilities storage (170)) and thus access propagation is known. This makes revocation of access achievable by recording a new transaction, which in effect removes the previous authorization. There will be no change to transaction history and instead a new transaction records (170) the current status of the capability. An example implementation on a blockchain system (180) is given in Ethereum, which allows programs called “smart contracts” to run as transactions.

Abstract: Communications along a neural pathway are provided. The neural pathway is stimulated at a first location, in order to evoke neural responses which propagate along the neural pathway, the neural responses being modulated with data. At a second location spaced apart from the first location along the neural pathway the evoked neural responses are sensed. The sensed neural responses are then demodulated to retrieve the data. The stimulation could comprise peripheral sensory stimulation, and the second location could be at an implanted electrode array.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.